Lupin's COPD Drug Revefenacin Receives Tentative FDA Green Light

Lupin Limited has announced receiving tentative approval from the U.S. Food and Drug Administration (FDA) for its Revefenacin Inhalation Solution, a treatment intended for the maintenance of Chronic Obstructive Pulmonary Disease (COPD).

Market Context and Sales Data

The drug targets a market segment similar to Mylan's Yupelri® Inhalation Solution. According to IQVIA data from March 2026, Yupelri® recorded estimated U.S. annual sales of USD 260.7 million.

Understanding 'Tentative' Status

The FDA's decision is currently tentative. This means that while the drug meets the agency's standards, further conditions or requirements must be met before Lupin can commercially launch Revefenacin in the United States.

Strategic Importance for Lupin

This regulatory step is significant for Lupin, potentially bolstering its respiratory drug portfolio in the U.S. market. A successful launch could contribute positively to revenue by tapping into a substantial market for COPD treatments, underscoring Lupin's capabilities in developing complex generic medications for key international markets.

Competitive Landscape in the U.S.

Lupin's entry into the COPD market occurs amidst a competitive environment. Major Indian pharmaceutical players such as Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., and Cipla Ltd. also maintain strong U.S. presences and compete in similar therapeutic areas, utilizing their established distribution and regulatory expertise.

What to Watch Next

The primary risk for Lupin is the tentative nature of the approval, requiring the company to fulfill outstanding FDA conditions for final clearance and commercial launch. Future monitoring will focus on confirmation of final FDA approval, Lupin's launch strategy and timeline, market reception, and the performance of Lupin's broader respiratory segment.